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Filaggrin-stratified transcriptomic analysis of pediatric skin
identifies mechanistic pathways in patients with atopic
dermatitis
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by a widespread abnormality in cutaneous barrier function and
propensity to inflammation. Filaggrin is a multifunctional
protein and plays a key role in skin barrier formation.
Loss-of-function mutations in the gene encoding filaggrin (FLG)
are a highly significant risk factor for atopic disease, but the
molecular mechanisms leading to dermatitis remain unclear.
Objective: We sought to interrogate tissue-specific variations in
the expressed genome in the skin of children with AD and to
investigate underlying pathomechanisms in atopic skin.
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82Uninvolved skin biopsy specimens from 26 pediatric patients
with AD were compared with site-matched samples from 10
nonatopic teenage control subjects. Cases and control subjects
were screened for FLG genotype to stratify the data set.
Results: Two thousand four hundred thirty differentially
expressed genes (false discovery rate, P < .05) were identified,
of which 211 were significantly upregulated and 490
downregulated by greater than 2-fold. Gene ontology terms for
‘‘extracellular space’’ and ‘‘defense response’’ were enriched,
whereas ‘‘lipid metabolic processes’’ were downregulated. The
subset of FLG wild-type cases showed dysregulation of genes
involved with lipid metabolism, whereas filaggrin
haploinsufficiency affected global gene expression and was
characterized by a type 1 interferon–mediated stress response.
Conclusion: These analyses demonstrate the importance of
extracellular space and lipid metabolism in atopic skin
pathology independent of FLG genotype, whereas an aberrant
defense response is seen in subjects with FLG mutations.
Genotype stratification of the large data set has facilitated
functional interpretation and might guide future therapy
development. (J Allergy Clin Immunol 2014;134:82-91.)
Key words: Atopic dermatitis, direct RNA sequencing, eczema,
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Atopic dermatitis (AD; atopic eczema or eczema) is an itchy
inflammatory skin disease with a spectrum of clinical skin
phenotypes.1,2 The pathology of eczematous skin is characterized
by epidermal intercellular edema and a barrier dysfunction
resulting in increased transcutaneouswater loss and increasedpene-
tration of external allergens and irritants.3 A subset of patients with
AD show greater susceptibility to bacterial4 and viral5 infection.
Previous studies have investigated the transcriptome in atopic
and eczematous skin by using microarray technologies and
quantitative PCR, identifying a variety of pathomechanisms,
including abnormalities in epidermal differentiation,6-8 inflam-
matory pathways,9-14 and lipid homeostasis.12,15,16 However,
microarray analysis is intrinsically restricted by preselection of
genes represented on an array and by annotations from which
gene expression is quantified.17 Sequencing RNA is now an
established methodology to study gene expression without the re-
striction of gene preselection.18 We chose to use single-molecule
direct RNA sequencing (DRS)19,20 as the optimal methodology
for quantification of the relatively small amounts of mRNA
available from pediatric skin biopsy samples. DRS offers accurate
quantification of polyadenylated RNA, avoiding bias that might
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amplification in other forms of RNA sequencing. In addition,
DRS provided information on the DNA strand from which the
mRNAwas transcribed; this facilitates more accurate alignment
of reads to genes in the complex overlapping regions that are
common in the human genome.21
The finding that loss-of-function mutations in the skin barrier
gene encoding filaggrin (FLG) are strongly and significantly
associated with AD risk22,23 has focused attention on skin
barrier dysfunction as a primary pathogenic mechanism.
Filaggrin deficiency appears to play a central role in the
pathogenesis of AD. Filaggrin expression can be downregulated
by TH2 cytokines
24-26 and atopic inflammation,27,28 whereas FLG
intragenic copy number variation influences AD risk in a
dose-dependent fashion, even in the absence of FLG null
mutations.29 Filaggrin is expressed initially as a long insoluble
polyprotein, profilaggrin, which is cleaved to produce
functional monomers that aggregate and align keratin filaments.30
Filaggrin is thereafter degraded in amultistep proteolysis to release
hygroscopic amino acids, contributing to the skin’s ‘‘natural mois-
turizing factor.’’31,32 Themechanisms bywhich themultifunctional
profilaggrin/filaggrin proteins lead to AD, as well as atopic asthma,
allergic rhinitis, food sensitization, and peanut allergy, have been
the focus of intense study over recent years.33
We sought to undertake a comprehensive analysis of the
primary molecular abnormalities in atopic skin using accurate
quantification of the transcriptome in pediatric patients with AD
compared with nonatopic teenage control subjects. FLG geno-
type was used to define subphenotypes for the stratification of
this large data set. Uninvolved skin was chosen to study the
underlying pathomechanisms of AD without the confounding
effects of secondary inflammation or infection. Our strategy for
analysis was stepwise, as follows: (1) all cases compared with
all control subjects, (2) case-control comparison stratified by
FLG genotype, and (3) case-case comparison stratified by FLG
genotype (Fig 1).METHODS
Study subjects: Patients with AD
This study was reviewed and approved by the research ethics board at
Our Lady’s Children’s Hospital, Dublin, Ireland (reference: SAC/119/09
26). Pediatric patients with AD of Irish ethnicity attending the dermatology
department were invited to participate. Twenty-six children aged 6 to 16
years and their parents/guardians provided written informed consent; 19
were male, and 7 were female (Table I). Each child had a history of
chronic relapsing AD diagnosed by experienced pediatric dermatologists
(G.M.O’R., R.M.W., A.D.I., and S.J.B.) and moderate or severe disease,
as defined according to the Nottingham Eczema Severity Score.34 Children
with a history of current or previous treatment with systemicimmunomodulatory medication were excluded. The area of biopsy was
not treated with topical steroids for 4 weeks before sampling, and emol-
lients were not applied for 2 days before biopsy. A single punch biopsy
specimen of 3 to 4 mm in diameter was taken from each child after local
anesthetic injection and standard aseptic technique from the upper outer
buttock skin. Clinically uninvolved skin was sampled and protected skin
on the buttock was chosen to minimize differences resulting from UV
exposure and variation in environmental humidity.35 Batch effects and
RNA degradation were minimized because samples were collected by 2
clinicians (G.M.O’R. and S.J.B.), and the biopsy specimens were immedi-
ately snap-frozen in liquid nitrogen before storage in a single 2808C
freezer before simultaneous processing. The study subjects had previously
provided blood samples for DNA extraction as part of the ongoing Na-
tional Children’s Research Centre AD Case Collection.36
Study subjects: Nonatopic control subjects
The collection of samples from healthy volunteers was reviewed and
approved by the East of Scotland Research Ethics Service, United Kingdom
(LR/11/ES/0043). Nonatopic teenage volunteers with 4 grandparents of Irish
or Scottish descent were recruited. Skin biopsy specimens were collected in
the same way as for the patients with pediatric AD, and 5 mL of venous blood
was collected for DNA extraction.
RNA extraction and quality control
The protocol for extraction of total RNA of greater than 200 nucleotides
in length from tissue by using the Qiagen RNeasy Mini Kit (Qiagen,
Manchester, United Kingdom) was modified and optimized, as follows.
Working on dry ice, subcutaneous fat was trimmed from the skin biopsy
specimen, and the remaining sample was placed in a 2-mL sample tube RB
(Qiagen, UK) with 600 mL of Buffer RLT (Qiagen, UK) and one 7-mm
stainless steel bead (Qiagen, UK). The sample was disrupted and homog-
enized at 48C in a Qiagen TissueLyser LT for 5 minutes at 50 oscillations
per second. RNA extraction then proceeded according to a standard
protocol with 2 final elution steps each using 30 mL of RNase-free water
and centrifuged at 12,000 rpm for 90 seconds. Spectrophotometry (Nano-
Drop ND-1000 spectrophotometer; Thermo Scientific, Uppsala, Sweden)
and a microfluidics platform for size analysis and quantification (Agilent
2100 Bioanalyser; Agilent Technologies, Santa Clara, Calif) were used for
quality control. This protocol yielded 2.5 to 10.8 mg per sample of RNA
with an A260/280 ratio of 1.9 to 2.1.
FLG genotyping
Genomic DNA samples extracted from blood were initially screened for
FLG null mutations with TaqMan allelic discrimination assays (TaqMan,
Applied Biosystems 7700 sequence detection system; Applied Biosystems,
Foster City, Calif), as previously described.37 Next-generation deep
sequencing of 25 cases and all 10 control subjects identified additional
mutations that were confirmed by using Sanger sequencing.Measurement of global transcript abundance
DRS was performed on a HeliScope Sequencer (Helicos, Cambridge,
Mass) with 500 ng of extracted RNA, as previously described.19 RNA mole-
cules are captured by the poly-A tail, and the single molecule of mRNA is
directly sequenced from the 39 end, producing reads up to 70 bp in length (me-
dian, 32 bp).DRS read processing
Details of sequence alignment and analysis are presented in the Methods
section in this article’s Online Repository at www.jacionline.org. DRS re-
sulted in 480 million reads across all 36 samples, providing gene expression
data for 11,259 genes. The raw data are deposited at the European Genome-
Phenome Archive (EGAS00001000823/EGAC00001000200); processed
data are available at polyAdb (http://www.compbio.dundee.ac.uk/polyAdb)
FIG 1. Flow diagram summarizing study design and analysis strategy. het, Heterozygous.
TABLE I. FLG genotype and demographic data for 26 pediatric
patients with moderate-to-severe AD and 10 nonatopic control
subjects
Phenotype FLG genotype No. (%)
Mean age
(y [range; SD])
Male sex,
no. (%)
Cases Wild-type 7 (27) 12.3 (9-15; 2.8) 7 (100)
Heterozygous 12 (46) 11.6 (6-16; 3.4) 8 (67)
Compound
heterozygous
7 (27) 10.7 (6-13; 3.4) 4 (57)
Total 26 11.5 (6-16; 3.2) 19 (73)
Control subjects Wild-type 8 (80) 17.9 (16-19; 0.8) 4 (50)
Heterozygous 2 (20) 18.0 (18-18; 0.0) 2 (100)
Compound
heterozygous
0 (0) NA 0 (0)
Total 10 17.9 (16-19; 0.7) 6 (60)
Cases were diagnosed by experienced pediatric dermatologists (G.M.O’R., R.M.W.,
A.D.I., and S.J.B.), and severity was defined by using the Nottingham eczema severity
score.34 Heterozygous mutations in the cases were p.R501X (n 5 6) and c.2282del4
(n 5 6), and those in the control subjects were p.R501X (n 5 1) and c.5690delA
(n 5 1). Compound heterozygous genotypes (each n 5 1) were p.R501X/c.2282del4,
p.R501X/p.S3247X, p.R501X/p.G1139X, p.R501X/p.S1280X, c.2282del4/p.R1474X,
p.S1040X/c.10885delC, and p.S608X/p.Y2092X.
NA, Not applicable.
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ensembl.org. Scripts for performing analysis and generating the figures that
accompany this article are available at polyAdb (http://www.compbio.
dundee.ac.uk/polyAdb).Differential gene expression and FLG correlation
analyses
EdgeR (version 2.6.12 in R version 2.15.1) analysis was performed with
generalized linear models to control for sex bias between comparisons. Unless
otherwise stated, genes were called as significantly differentially expressed if
the Benjamini-Hochberg corrected false discovery rate (FDR) was less than
0.05.38 All-against-all correlation of gene expression across individual sam-
ples was performed with the Pearson method. Further details are presented
in the Methods section in this article’s Online Repository.
Gene ontology analysis and functional protein
network analysis
Gene ontology (GO) has been developed to provide a controlled vocabulary
of terms to describe the characteristics of genes and gene products with
standardization across species and between databases. This allows the
bioinformatic analysis of GO terms in large data sets for thematic classifica-
tion. GO analyses were performed with AmiGO gene ontology version 1.8
(http://amigo.geneontology.org/cgi-bin/amigo/search.cgi?action5advanced_
query). Functional protein association networks were investigated in silico by
using STRING9.05 (http://string-db.org/).
Quantitative PCR analysis
RNA (1.4 ng) was converted to cDNA by using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems), according to a standard
protocol. Aliquots of RNA extracted from atopic skin samples were analyzed
in triplicate by using real-time quantitative PCR performed according to
standard protocols with the TaqMan 7900HT Fast (Applied Biosystems) with
normalization to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
FIG 2. Scatterplots showing correlation of gene expression levels with FLG expression. The fold change of
significantly differentially expressed genes (FDR P < .05) is plotted against the Pearson correlation
coefficient for correlation with FLG expression. Each point represents expression of a single gene. FLG is
marked in orange. A, Correlation of FLG wild-type (n 5 7) compared with FLG heterozygous (n 5 12)
samples. B, Correlation of FLG wild-type (n 5 7) versus FLG compound heterozygous (n 5 7) samples.
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Seventy-three percent of patients with AD carry 1 or
more FLG null mutations
Our comprehensive screen for FLG null mutations revealed a
high proportion of mutation carriers (19/26 [73%] of cases,
Table I), reflecting the severity of disease and enrichment for
coexisting ichthyotic skin phenotype. One heterozygous
mutation, p.Y2092X, is reported for the first time. Two (20%)
of 10 control subjects were heterozygous for an FLG null
mutation (Table I).FLG genotype affects global gene expression
Gene expression between samples was highly correlated
(Pearson r 5 0.81-0.99, see Fig E1 in this article’s Online
Repository at www.jacionline.org), and comparison of the control
samples with AD cases revealed no obvious clustering by
phenotype or FLG genotype (see Fig E2 in this article’s Online
Repository at www.jacionline.org). This highlights the subtlety
of changes in gene expression in uninvolved atopic skin. The
samples do not cluster according to age, providing some
assurance that the use of samples from older subjects in the
control group does not result in bias to account for the observed
differences in transcriptional profile. However, in contrast,
correlation with FLG gene expression showed a striking global
change between samples of different FLG genotypes (Fig 2).‘‘Defence response’’ and ‘‘extracellular region’’
genes are overexpressed in atopic skin, whilst ‘‘lipid
metabolic processes’’ and ‘‘small molecule
metabolic processes’’ are downregulated
Comparing all 26 cases with all 10 control subjects showed
2430 differentially expressed geneswith an FDR of less than 0.05,including 211with a fold change of greater than 2.0 and 490 genes
with a fold change of less than 0.5. The full list is shown in
Table E1 in this article’s Online Repository at www.jacionline.
org. GO analysis identified the most highly significant terms in
the greater than 2.0-fold upregulated genes as ‘‘defense response’’
(28 genes, FDR: P5 7.13 10207), the ‘‘extracellular region’’ or
‘‘extracellular space’’ (each 32 genes, FDR: P5 1.83 1023) and
‘‘receptor binding’’ (23 genes, FDR: P 5 5.7 3 1023). The
most highly significant terms in the less than 0.5-fold
downregulated genes were ‘‘lipid metabolic process’’ (52 genes,
FDR: P 5 6.6 3 10211), ‘‘small molecule metabolic process’’
(76 genes, FDR: P5 6.63 10211), and ‘‘organic acid metabolic
process’’ (44 genes, FDR: P 5 6.6 3 10211). The full list
is shown in Table E2 in this article’s Online Repository at
www.jacionline.org.
Analysis of the significantly upregulated genes identified
predicted protein interaction networks classified as ‘‘defense
response,’’ ‘‘extracellular region,’’ and ‘‘receptor binding’’ (see
Fig E3 in this article’s Online Repository at www.jacionline.org).
Significantly downregulated genes show predicted functional net-
works within ‘‘lipid metabolic processes,’’ ‘‘small molecule meta-
bolism,’’ and ‘‘organic acid metabolic processes’’ (see Fig E4 in
this article’s Online Repository at www.jacionline.org).FLG wild-type subjects show dysregulation of
genes involved with lipid metabolism and
upregulation of extracellular matrix terms
Analysis of the 8 FLG wild-type control subjects compared
with the 7 FLG wild-type cases identified 401 differentially
expressed genes with an FDR of less than 0.05, including 105
with a fold change of greater than 2.0 and 87 with a fold
change of less than 0.5 (the full list can be found in Table E3
in this article’s Online Repository at www.jacionline.org).
FIG 3. Network analysis of lipid metabolism genes differentially expressed in FLG wild-type AD cases
compared with FLG wild-type control subjects. Twenty-one significantly differentially expressed genes
(defined as FDR: P < .05 and fold change >2.0 or <0.05) were classified with the GO terms ‘‘lipid metabolic
process’’ (n5 13), ‘‘cellular lipid metabolism’’ (n5 13), ‘‘lipid particle’’ (n5 4), and ‘‘triglyceride catabolism’’
(n 5 3). Linear connectors indicate evidence for association in published data sets (STRING9.05; accessed
March 3, 2014).
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fold included ‘‘extracellular region’’ (17 genes, FDR: P 5 3.0 3
1023) and ‘‘lipid particle’’ (4 genes, FDR: P 5 3.0 3 1023).
Significantly downregulated transcripts (fold change <0.5) were
classified with the GO terms ‘‘cellular lipid metabolic process’’
(13 genes, FDR: P5 1.63 1023) and ‘‘lipid metabolic process’’
(13 genes, FDR: P 5 2.7 3 1022; the full list can be found in
Table E2). In silico protein network analysis of the differentially
expressed lipid metabolism genes shows a predicted network
involving both upregulated and downregulated transcripts (Fig 3).Case-control analysis stratified by FLG genotype
shows upregulated defense response cytokines and
downregulated ‘‘steroid metabolic process’’
Analysis stratified according to FLG genotype was
performed to investigate the mechanisms by which filaggrin
haploinsufficiency might predispose to the development of AD.
The 8 FLG wild-type control subjects were compared with the
7 compound heterozygous cases, revealing 816 differentially
expressed transcripts (FDR <0.05). These included 137 with a
fold change of greater than 2.0 and 266 with a fold change of
less than 0.5 (the full list can be found in Table E4 in this article’s
Online Repository at www.jacionline.org). Significant GO terms
in the upregulated transcripts included ‘‘defense response’’
(17 genes, FDR: P 5 2.3 3 1024) and ‘‘response to biotic
stimulus’’ (14 genes, FDR: P 5 2.3 3 1024), ‘‘chemokineactivity’’ (5 genes, FDR: P 5 1.3 3 1023), and ‘‘chemokine
receptor binding’’ (5 genes, FDR: P5 1.33 1023; full list shown
Table E2). In silico protein network analysis of the upregulated
transcripts demonstrated a functional network of chemokines
and cytokines in the defense response, including both TH1- and
TH2-associated transcripts: CXCL9, CXCL10, CCL13, CCL18,
SELE, IFI27, and IRF1 (see Fig E5, A, in this article’s Online
Repository at www.jacionline.org). The most significant GO
term in the transcripts downregulated less than 0.5-fold was
‘‘steroid metabolic process’’ (14 genes, FDR: P 5 3.6 3 1023,
see Table E2).
Analysis of the 8 FLG wild-type control subjects compared
with 12 FLG heterozygous cases revealed 1139 differentially
expressed transcripts (FDR, <0.05) in which 104 are
significantly upregulated (fold change, >2.0) and 313 are
significantly downregulated (fold change, <0.5; the full list can
be found in Table E5 in this article’s Online Repository at
www.jacionline.org). The upregulated transcripts showed
enrichment for GO terms in the ‘‘defense response’’ (16 genes,
FDR: P 5 7.6 3 1023) forming a predicted protein network
analogous to that seen in the wild-type control subject
versus compound heterozygous case comparison, with the
addition of GRIN2B, GRIK2, and MNDA (see Fig E5, B).
Genes classified for the ontology terms ‘‘receptor binding’’
(15 genes, FDR: P5 2.93 10212), ‘‘cytokine activity’’ (7 genes,
FDR: P 5 2.9 3 10212), and ‘‘extracellular region’’ (19 genes,
FDR: P 5 3.2 3 1026) were also significantly upregulated. The
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less than 0.5-fold were ‘‘small molecule metabolic process’’
(60 genes, FDR: P 5 3.1 3 10210), ‘‘carboxylic acid metabolic
process,’’ and ‘‘oxoacid metabolic process’’ (each 35 genes and
FDR: P 5 3.1 3 10210; the full list can be found in Table E2).FIG 4. Box plot showing FLGmRNA read counts in different AD phenotypesFLG mRNA shows a stepwise reduction in patients
with AD, and there might be upregulation of
expression in FLG wild-type atopic skin
FLG mRNA–normalized read counts show a stepwise
reduction from FLG wild-type to FLG heterozygous and
compound heterozygous patients with AD (Fig 4). This indicates
that a form of nonsense-mediated decay occurs in the context of
an FLG null mutation, although mature mRNA transcripts are
still detectable even in those subjects with 2 FLG null mutations
(Fig 4). Comparison of all cases with all control subjects showed
no significant difference in FLGmRNA levels (P >.05), but there
is significantly greater mRNA expression in wild-type AD cases
than wild-type control subjects (P 5 3.0 3 1023), suggesting
that there might be a compensatory upregulation of FLG
mRNA in atopic skin of FLG wild-type subjects.and FLG genotypes. Gene expression was normalized across all
samples with EdgeR: 8 wild-type control subjects, 7 wild-type AD cases,
12 heterozygous cases, and 7 compound heterozygous cases.Differentially expressed transcripts at loci near to
regions identified by genome-wide association
studies indicate expression quantitative trait loci
Significantly differentially expressed transcripts in the
case-control analysis were compared with AD-associated single
nucleotide polymorphisms from published genome-wide
association studies (see the Methods section in this article’s
Online Repository). Seventeen putative expression quantitative
trait loci (cis-eQTLs) were identified on the basis of a transcript
proximity of less than 250 kb between the single nucleotide
polymorphism site and the 59 end of the transcript (see Table
E6 in this article’s Online Repository at www.jacionline.org).39
Four of the proposed cis-eQTLs correspond to previously
reported AD candidate genes (FLG, TNXB, C11ORF30, and
ZNF652), whereas 13 represent novel candidates (see Table E6).Analysis of cases stratified by FLG genotype shows
differential expression of cartilage intermediate
layer protein (CILP)
A comparison of the 26 cases stratified by FLG genotype was
performed to investigate filaggrin-associated mechanisms in
AD pathogenesis; this comparison also represents the most
closely matched samples to control for age-specific differences.
A total of 201 genes were differentially expressed (unadjusted
P < .01): 87 genes were differentially expressed in the FLG
wild-type cases versus compound heterozygous cases, and 127
were differentially expressed in thewild-type versus heterozygote
comparison (see Table E7 in this article’s Online Repository at
www.jacionline.org). Forty-one genes showed a fold change of
greater than 2.0 or less than 0.5. After controlling for multiple
testing, 2 genes showed a statistically significant difference in
expression: FLG (FDR: P 5 6.1 3 10212; fold change, 0.3) and
cartilage intermediate layer protein (CILP; FDR: P 5 .03; fold
change, 0.2). The differential expression of FLG, CILP, and
selected other transcripts was validated by using quantitative
PCR with aliquots of the previously extracted RNA samples(see Table E8 in this article’s Online Repository at www.
jacionline.org).
GO analysis of the 127 transcripts showing differential
expression between FLG wild-type and compound heterozygous
cases showed the highest number of genes to be associated
with ‘‘extracellular region’’ (28 genes, including FLG
and CILP; FDR: P 5 8.7 3 1023), ‘‘carbohydrate binding’’
(12 genes, FDR: P 5 5.6 3 1023), and ‘‘calcium ion binding’’
(14 genes, including FLG; FDR: P 5 .02; the full list can be
found in Table E9 in this article’s Online Repository at www.
jacionline.org).FLG expression correlates with gene expression in
the extracellular space and is anticorrelated with a
network of defense response genes
Correlation of gene expression with FLG expression was used
to investigate filaggrin-related mechanisms and pathways in
atopic skin. Twenty genes show strong correlation with FLG
expression (each r > 0.98 and P < .05), including 7 classified
within the extracellular region: CA2 (carbonic anhydrase 2),
COL12A1 (collagen, type XII, alpha 1), MUCL1 (mucin-like 1),
PIP (prolactin-induced protein), PRELP (proline/arginine-rich
and leucine-rich repeat protein), SCGB1D2 (secretoglobin,
family 1D, member 2), and ZG16B (zymogen granule protein
16 homolog B; the full list can be found in Table E10 in this
article’s Online Repository at www.jacionline.org).
The expression levels of 6 genes were strongly anticorrelated
withFLG expression (each r <20.98, see Table E10); 5 of these 6
genes formed a predicted network (Fig 5). Significant GO terms
associated with this network include ‘‘response to virus’’ (4 genes,
FDR: P 5 5.1 3 1023), ‘‘cellular response to type I interferon,’’
‘‘response to type I interferon,’’ and ‘‘type I interferon–mediated
signaling pathway’’ (each 3 genes, FDR: P 5 6.3 3 1023).
Combining these 6 anticorrelated and upregulated genes with
J ALLERGY CLIN IMMUNOL
JULY 2014
88 COLE ET ALthe 17 defense response genes that are upregulated in the FLG
genotype–stratified case-control analyses (see Table E2) shows
a common predicted functional network of ‘‘defense response’’
(20 genes, FDR: 5.6 3 10218; Fig 6).FIG 5. Network analysis of 6 genes with expression strongly anticorrelated
with FLG expression: TRIM22 (tripartite motif containing 22), KCNK1
(potassium channel, subfamily K, member 1), PARP9 (poly (ADP-ribose)
polymerase family, member 9), IFITM2 (interferon induced transmembrane
protein 2), IFITM1 (interferon induced transmembrane protein 1), and
STAT1 (STRING9.05; accessed October 27, 2013).DISCUSSION
The identification of genes involved in the pathogenesis of AD
represents a significant challenge because of the clinical
heterogeneity and complexity of multiple interrelated genetic
and environmental mechanisms in patients with this disease. The
identification of null mutations within the gene encoding filaggrin
(FLG) as a strong and significant risk factor for AD22 represented
a fundamental breakthrough in understanding pathogenesis.33
The strong effect of filaggrin haploinsufficiency can be used to
define AD subphenotypes clinically,40 and we have applied this
insight for stratification of the large and complex data set
generated by using transcriptomic analysis.
This study used DRS to quantify the whole transcriptome of
atopic skin in a unique collection of pediatric AD skin biopsy
specimens; it represents the largest collection of AD skin tran-
scriptomes reported to date. Skin offers the advantage of sampling
the tissue of interest, maximizing power to detect expression traits
correlating with clinical phenotype.41 Importantly, the histopathol-
ogy of clinically uninvolved atopic skin demonstrates an absence
of inflammatory cell infiltrate, and gene expression changes are
therefore likely to represent keratinocyte-related mechanisms
rather than those from any other cell type. The skin of patients
with AD shows epidermal barrier dysfunction, which can be
demonstrated in nonlesional (clinically uninvolved) skin, as well
as areas of active eczema.42,43 Nonlesional skin was sampled to
focus on the intrinsic biological abnormality in atopic skin and
to exclude, as far as possible, the secondary effects of inflammation
in patients with active dermatitis and secondary infection, which
would confound themRNAprofile.6,10 The cutaneous gene expres-
sion profile is known to vary by age, sex, and, most significantly,
body site.44 This study included case-case comparison for optimal
matching in age and skin site, and our case-control samples were
carefully matched for body site and sex. Age matching in the
case-control analysis was limited by the availability of skin biopsy
samples fromhealthy children; however, the data obtained frombi-
opsy specimens of teenage volunteers showed no clustering by age
(see Fig E2). Furthermore, the differentially expressed defense
response genes formed an overlapping network with the
age-matched case-case analyses. DRS allows accurate
quantification of mRNA species. The confirmation of findings
from previous microarray studies and consistency with our own
quantitative PCR studies provide support for the validity of DRS
as a novel technique for the investigation of AD pathogenesis.
We have shown that genes encoding proteins in the extracellular
space are differentially expressed in atopic skin, with upregulation
in patients with AD compared with that seen in control subjects
(see Table E2). Conversely, 7 genes encoding proteins in the extra-
cellular region are downregulated in strong correlation with FLG
expression (see Table E10). These genes are likely to contribute
to mechanisms by which a quantitative reduction in intracellular
filaggrin levels results in the paracellular barrier defect that is
observed in vitro.45,46 Expression of CILP shows the most signifi-
cantly reduced expression in FLG null cases compared with FLG
wild-type cases and might represent a novel AD candidate gene.
The protein encoded by CILP is expressed in many tissues,including skin and blood, as well as articular cartilage. It is
secreted into the extracellular space and sequesters growth factors,
cytokines, and matrix metalloproteases in the extracellular matrix.
Also, it has been shown to antagonize the actions of TGF-b1 and
insulin-like growth factor 1.47,48We hypothesize that a reduction in
expression of the cartilage intermediate layer protein permits
increased activity of insulin-like growth factor 1 and TGF-b1,
leading to cellular proliferation, whereas a reduction in the seques-
tration of proinflammatory cytokines and metalloproteases in the
extracellular space might simultaneously contribute to skin
barrier dysfunction in cases of AD associated with filaggrin
deficiency.
The second major finding of this global transcriptomic analysis
is the dysregulation of lipid metabolic pathways both in the
unstratified case-control comparison (see Fig E4, A) and in the
FLG wild-type case-control comparison (Fig 3). The demonstra-
tion of lipid dysregulation predominantly in the cases without
FLGmutations is in keeping with in vivo49 and in vitro50 findings
that filaggrin deficiency does not affect lipid composition in the
stratum corneum. Previous microarray analyses have shown a
reduction in expression of lipid homeostatic genes12 and reduced
intercellular lipid levels.15 Organotypic culture of primary
keratinocytes has shown increased expression of a cluster of
genes associated with lipidmetabolism throughout differentiation
in parallel with increasing barrier properties.51 Lipid raft
disruption produces transcriptomic changes in cultured
keratinocytes, including disruption of cholesterol biosynthesis,
that mimic changes seen in patients with AD.16 The predicted
functional network in Fig 3 comprises upregulated and
downregulated lipid metabolism genes and might offer insight
into the complex interplay of metabolic dysfunction with
systemic inflammation.52 Genes encoding proteins involved
with very long-chain fatty acid CoA ligase activity are
downregulated, which is in keeping with the observation that
ceramides and long-chain fatty acids play an important role in
skin barrier formation.49,53,54 Our stratified analysis indicates
that therapies aimed to restore skin lipid composition might be
most beneficial to FLG wild-type patients.
The FLG-stratified case-control and case-case comparisons
have identified an overlapping functional network of proteins
forming a type 1 interferon–mediated defense response (Fig 6).
The upregulation of this networkmight relate to the dysfunctional
cutaneous response to viral infection in patients with AD, which
FIG 6. Genes anticorrelated with FLG and upregulated in FLG mutant cases show a common network of
stress response. Six genes are anticorrelated (upregulated) with FLG expression, and 17 genes are
upregulated in the FLG genotype–stratified case-control analyses. Proteins encoded by genes classified
with the GO term ‘‘response to stress’’ are colored red (STRING9.05; accessed November 16, 2013).
J ALLERGY CLIN IMMUNOL
VOLUME 134, NUMBER 1
COLE ET AL 89can be a significant problem in clinical practice.5 Alternatively, it
might represent a suboptimal, partially functional mechanism to
compensate for the increased frequency of viral infections,
including eczema herpeticum,55 seen in filaggrin-deficient
subjects. The signal transducer and activator of transcription
(STAT) encoded by STAT1 contributes to the transcriptional
control of several interferon-stimulated genes, including IFITM1,
IFITM2, IFI27, and GBP1. The Janus kinase/STAT signaling
pathway plays a key role in transmembrane signaling from
the TH2 cytokines IL-4 and IL-13, which predominate
in acute AD.56 IFITM1 and IFITM2 encode interferon-induced
transmembrane proteins, which contribute to the control of cell
growth through a multimeric complex involved in the transduc-
tion of antiproliferative and homotypic adhesion signals; they
are induced by IFN-g in primary keratinocytes in vitro and have
been proposed to play a role in keratinocyte apoptosis in patients
with AD.57 The chemokine network encoded by genes including
CCL13, CCL18, CXCL9, and CXCL10 has been implicated in the
pathogenesis of AD in some of the previous microarray
studies.9,11,13,58 Filaggrin haploinsufficiency increases the risk
of eczema herpeticum,59 and the functional network predicted
by transcriptomic analysis indicates a pathway that might be tar-
geted for therapeutic intervention in susceptible patients.
The quantitative reduction in filaggrin mRNA with FLG
null mutations (Fig 4) is consistent with previous studies
showing a stepwise reduction in filaggrin breakdown productsin FLG heterozygotes and FLG homozygotes or compound
heterozygotes.27,60 One previous microarray study has used
FLG genotype–stratified analysis8 and reported no significant
difference in FLG mRNA levels between FLG wild-type cases
and control subjects. In our analysis comparison of all cases
with all control subjects also showed no difference in FLG
mRNA counts (P > .05), but we have shown a significant
difference between FLG expression in wild-type control subjects
compared with wild-type cases (Fig 4). This is compatible with
the confidence range of data published previously8 but suggests
that theremight be compensatory upregulation ofFLG expression
in our pediatric AD cases. An alternative explanation is that
there might be lower filaggrin expression in our control
subjects, possibly reflecting the slightly older age, but detailed
studies of filaggrin expression changes with aging are not
currently available.
Intercellular edema (spongiosis) is a characteristic feature in
patients with AD, but the underlyingmechanisms are unclear. The
differential expression of genes encoding proapoptotic and
antiapoptotic proteins (including IGFBP6, CLU, IFITM1,
IFITM2, SELE, CXCL10, PRF1, and IRF1) might contribute to
the propensity to keratinocyte apoptosis that some authors
consider to be a key pathomechanism in atopic spongiosis.57,61,62
Alternatively, the dysregulation of proteins in cell death pathways
might reflect the specialized process of keratinocyte cell death,
cornification.63,64
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90 COLE ET ALThe majority of AD risk loci identified by using genome-wide
association studies are located within intergenic regions of
unknown function. Our analysis has offered insight into
possible genetic mechanisms associated with 14 of the previously
reported AD risk loci. We propose cis-eQTLs indicating a
range of pathomechanisms, including structural (FLG, LCE3E,
and TNXB), immune response (CST6, HLA-DRA, IRF1,
and PRRT1), transcriptional regulation (ATF6B, C11orf30,
RP11-21L23.4, RPL3P2, RPSAP47, SIPA1, and ZNF652),
mitochondrial (TST), and lipid biosynthetic (AGPAT1).
The use of DRS has allowed detailed study of tissue-specific
gene expression data from small amounts of tissue. This
transcriptomic analysis has provided new insight into the
mechanistic pathways in atopic skin, which are both
dependent and independent of FLG genotype. The strength of
using a functional genotype for phenotype stratification is
apparent, and this approach might prove useful for other
tissue-specific inflammatory disorders and personalized medicine
in the future.
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Key messages
d Atopic skin shows differential gene expression in
pathways classified in the extracellular space, lipid
metabolism, and stress response.
d Substratification of the whole transcriptome data set
according to FLG genotype reveals a type 1 interferon–
mediated stress response in filaggrin-deficient skin.
d These findings offer insight into the underlying
abnormalities in uninflamed atopic skin and might guide
future therapy development.REFERENCES
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